Most women with a common form of breast cancer did not benefit from the chemotherapy drug Taxol, but the drug was effective in treating women with overactive HER-2 genes, scientists report. The findings were based upon new investigation of research from the 1990s, but the new study's lead researcher says more work should be done before "withholding it (Taxol) from some patients."

Full Story:

Related Summaries